These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12609691)

  • 41. Construction and characterization of a fluorescent sendai virus carrying the gene for envelope fusion protein fused with enhanced green fluorescent protein.
    Miyazaki M; Segawa H; Yamashita T; Zhu Y; Takizawa K; Hasegawa M; Taira H
    Biosci Biotechnol Biochem; 2010; 74(11):2293-8. PubMed ID: 21071846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient and stable Sendai virus-mediated gene transfer into primate embryonic stem cells with pluripotency preserved.
    Sasaki K; Inoue M; Shibata H; Ueda Y; Muramatsu SI; Okada T; Hasegawa M; Ozawa K; Hanazono Y
    Gene Ther; 2005 Feb; 12(3):203-10. PubMed ID: 15483665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.
    Kawana-Tachikawa A; Tomizawa M; Nunoya J; Shioda T; Kato A; Nakayama EE; Nakamura T; Nagai Y; Iwamoto A
    J Virol; 2002 Dec; 76(23):11982-8. PubMed ID: 12414940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Strategy to Control Transgene Expression Mediated by a Sendai Virus-Based Vector Using a Nonstructural C Protein and Endogenous MicroRNAs.
    Sano M; Iijima M; Ohtaka M; Nakanishi M
    PLoS One; 2016; 11(10):e0164720. PubMed ID: 27764162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication.
    Sakai Y; Kiyotani K; Fukumura M; Asakawa M; Kato A; Shioda T; Yoshida T; Tanaka A; Hasegawa M; Nagai Y
    FEBS Lett; 1999 Aug; 456(2):221-6. PubMed ID: 10456313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes.
    Murakami Y; Ikeda Y; Yonemitsu Y; Tanaka S; Kondo H; Okano S; Kohno R; Miyazaki M; Inoue M; Hasegawa M; Ishibashi T; Sueishi K
    J Gene Med; 2008 Feb; 10(2):165-76. PubMed ID: 18074401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New cancer therapy using genetically-engineered oncolytic Sendai virus vector.
    Kinoh H; Inoue M
    Front Biosci; 2008 Jan; 13():2327-34. PubMed ID: 17981715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies.
    Moriya C; Horiba S; Kurihara K; Kamada T; Takahara Y; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Matano T
    Vaccine; 2011 Nov; 29(47):8557-63. PubMed ID: 21939708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Knockout serum replacement (KSR) has a suppressive effect on Sendai virus-mediated transduction of cynomolgus ES cells.
    Kishi Y; Inoue M; Tanaka Y; Shibata H; Masuda S; Ikeda T; Hasegawa M; Hanazono Y
    Cloning Stem Cells; 2008 Sep; 10(3):307-12. PubMed ID: 18729764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.
    Moriya C; Horiba S; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Matano T
    Biochem Biophys Res Commun; 2008 Jul; 371(4):850-4. PubMed ID: 18466766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
    Kinoh H; Inoue M; Komaru A; Ueda Y; Hasegawa M; Yonemitsu Y
    Gene Ther; 2009 Mar; 16(3):392-403. PubMed ID: 19037241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of deletion of envelope-related genes of recombinant Sendai viruses on immune responses following pulmonary gene transfer of neonatal mice.
    Tanaka S; Yonemitsu Y; Yoshida K; Okano S; Kondo H; Inoue M; Hasegawa M; Masumoto K; Suita S; Taguchi T; Sueishi K
    Gene Ther; 2007 Jul; 14(13):1017-28. PubMed ID: 17460720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of the rescue efficiency of Sendai virus minigenome mediated by CMV and T7 promoter].
    Wei GC; Tian WH; Wang G; Liu YF; Yu CJ; Dong XY; Ling H; Wu XB
    Bing Du Xue Bao; 2012 May; 28(3):237-45. PubMed ID: 22764526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression.
    Li HO; Zhu YF; Asakawa M; Kuma H; Hirata T; Ueda Y; Lee YS; Fukumura M; Iida A; Kato A; Nagai Y; Hasegawa M
    J Virol; 2000 Jul; 74(14):6564-9. PubMed ID: 10864670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions.
    Liu X; Yan Z; Luo M; Zak R; Li Z; Driskell RR; Huang Y; Tran N; Engelhardt JF
    J Virol; 2004 Apr; 78(8):4165-75. PubMed ID: 15047832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Cloning and expression of the six coding genes of sendai virus BB1 strain].
    Zhang HF; Yang Y; Dong XY; Wu XB
    Bing Du Xue Bao; 2009 May; 25(3):213-9. PubMed ID: 19634765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation of the beta interferon promoter by unnatural Sendai virus infection requires RIG-I and is inhibited by viral C proteins.
    Strähle L; Marq JB; Brini A; Hausmann S; Kolakofsky D; Garcin D
    J Virol; 2007 Nov; 81(22):12227-37. PubMed ID: 17804509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.
    Kiener R; Fleischmann M; Wiegand MA; Lemmermann NAW; Schwegler C; Kaufmann C; Renzaho A; Thomas S; Felder E; Niller HH; Asbach B; Wagner R
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29769344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene.
    Shibata S; Okano S; Yonemitsu Y; Onimaru M; Sata S; Nagata-Takeshita H; Inoue M; Zhu T; Hasegawa M; Moroi Y; Furue M; Sueishi K
    J Immunol; 2006 Sep; 177(6):3564-76. PubMed ID: 16951315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.